Tabalumab

Summary

Tabalumab (CHEMBL1743075) is a phase-3 clinical-stage antibody; indicated across 5 conditions including rheumatoid arthritis and systemic lupus erythematosus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 5 conditions
• Clinical trials: 21

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743075
Name	Tabalumab
Type	Antibody
Max phase	3

Also known as: LY-2127399, LY2127399, Tabalumab, TABALUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
systemic lupus erythematosus	3	MONDO:0007915	MONDO:0007915
relapsing-remitting multiple sclerosis	2	MONDO:0005314	EFO:0003929
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
chronic kidney disease	2	MONDO:0005300	MONDO:0024327

Clinical trials

Total trials: 21.

Phase distribution

Phase	Trials
PHASE3	9
PHASE2	8
PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01196091	PHASE3	COMPLETED	A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01198002	PHASE3	TERMINATED	A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
NCT01202760	PHASE3	COMPLETED	A Rheumatoid Arthritis Study in Participants
NCT01202773	PHASE3	TERMINATED	A Study in Participants With Rheumatoid Arthritis
NCT01205438	PHASE3	COMPLETED	A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01215942	PHASE3	TERMINATED	An Open Label Study for Participants With Rheumatoid Arthritis
NCT01488708	PHASE3	TERMINATED	On Open-Label Study in Participants With Systemic Lupus Erythematosus
NCT01676701	PHASE3	TERMINATED	Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)
NCT02041091	PHASE3	TERMINATED	A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
NCT00308282	PHASE2	COMPLETED	A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis
NCT00689728	PHASE2	COMPLETED	A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy
NCT00785928	PHASE2	COMPLETED	A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
NCT00837811	PHASE2	COMPLETED	An Open Label Extension Study in Participants With Rheumatoid Arthritis
NCT00882999	PHASE2	COMPLETED	A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01200290	PHASE2	COMPLETED	A Study in Participants With End-Stage Renal Disease
NCT01576549	PHASE2	TERMINATED	A Study of LY2127399 in Rheumatoid Arthritis
NCT01602224	PHASE2	COMPLETED	A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
NCT00689507	PHASE1	COMPLETED	A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
NCT01253226	PHASE1	COMPLETED	A Study for Japanese Participants With Rheumatoid Arthritis (RA)
NCT01253291	PHASE1	COMPLETED	A Study of Japanese Rheumatoid Arthritis Participants
NCT01556438	PHASE1	COMPLETED	Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).